Trial of Tirzepatide for the Treatment of Cannabis Use Disorder

What Was Tested

The trial (phase 2) is built around Tirzepatide.

It had two arms (groups): Active Treatment (experimental) and Placebo (placebo comparator).

The registry classes the interventions as drug.

More on the Plan

This is a double-blind, placebo-controlled, randomized clinical trial. 100 individuals with moderate to severe cannabis use disorder (CUD) will be randomized in a 1:1 ratio to receive either (1) weekly subcutaneous injections of tirzepatide or (2) weekly subcutaneous injections of matching placebo for 24 weeks.

Who Took Part

Enrollment: 100 planned participants were the target.

It was open to people of any sex aged from 18 years up to 70 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Between 18 and 70 years of age. Meets DSM-5 criteria for moderate or severe CUD. Interested in treatment for cannabis use disorder. Able to understand the study procedures and written informed consent in English. Willing to comply with all study procedures and medication instructions.

The full record lists 6 inclusion and 8 exclusion criteria; among the exclusions: body mass index (bmi) ≤ 23 kg/m²; presence of a medical or psychiatric disorder that contraindicates participation in the study; substance use disorder other than tobacco or mild alcohol-use disorder.

How the Study Was Run

Design: randomized, parallel-group and triple-blind.

Because people in this Tirzepatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The Tirzepatide group and the comparison group ran side by side rather than switching.

Neither the participants nor the staff measuring them knew who was on Tirzepatide, so expectations could not easily colour the readings.

Those kept unaware of assignments: participant, investigator and outcomes assessor.

It started in 2026-11-15 with completion listed for 2028-03-15.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Days of Abstinence (time frame: 24 weeks (Treatment Phase)).

It also tracked 6 secondary outcomes, for example Severity of Cannabis Use Disorder (CUD), Negative Urine Drug Screens (UDS), Cannabis Craving, 1. Cannabis Withdrawal, Retention in Treatment and Quality of Life.

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Tirzepatide in 100 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page, all human trials.